BU is commonly used in combination with fludarabine or CY for conditioning before hematopoietic SCT due to a favorable toxicity profile. 1, 2 However, as the pharmacokinetics (PK) of BU can be unpredictable there is interpatient variability in the systemic concentrations of the drug after weight-based dosing. Supra-therapeutic levels may increase the risk of non-relapse mortality, 3 whereas sub-therapeutic levels may lead to disease relapse. 4 Therapeutic drug monitoring has been attempted to tailor the dose for each patient and achieve a target area under the curve (AUC). 5 For this reason, blood sampling strategies have been adopted to determine the BU dose required to achieve a desired target AUC. 6 Although the exact mechanism of BU metabolism is unknown, it is believed that the drug undergoes glucuronidation and subsequent metabolism through the liver. 7 Therefore, there is potential for drug-drug interactions that may increase or decrease the clearance of BU. Newer drugs are now being introduced into the SCT arena, but their effect on BU metabolism remains unknown. We describe a case that demonstrates the significant effect of deferasirox on BU blood concentrations.
A 59-year-old female with a 4-year history of transfusion-dependent hypoplastic MDS resistant to treatment with immunosuppression was referred for allo-SCT from a matched related donor after progression to refractory anemia with excess of blasts 2 (RAEB-2). At 2 weeks before a myeloablative transplant conditioned with the FluBu regimen, she was electively admitted to receive a BU test dose at 0.8 mg/kg administered intravenously. The target AUC for the pre-transplant test dose is 1200 mM min. This patient was given 48 mg of BU after which eight blood samples were drawn to determine her BU AUC. Blood samples were processed and shipped to the Seattle BU PK Laboratory for analysis. Her AUC was reported as 1868 mM min with a BU clearance rate of 1.74 mL/min/kg. On the basis of these results, a 124-mg dose would be given for each daily dose for the conditioning regimen. Her AUC was noted to be higher than expected, especially given the absence of any liver dysfunction or known drug interactions extrapolated from patient history that would increase the levels. The patient was re-admitted after 1 month to start her preparative regimen. There were no documented changes in her home medications based on a discussion with the patient and her family. PK studies were again conducted for the first of four doses of BU for the conditioning regimen. The target AUC for each dose of the conditioning regimen is 4800 mM min. Her AUC was reported as 4692 mM min with a clearance rate of 2.76 mL/ min/kg, both of which correlated with normal and expected values for the patient. On the basis of these results, the dose for SCT would be 215 mg, twice the dose that was determined pre-transplant.
After further investigation of home medications, it was noted that the patient had previously been taking deferasirox for iron overload due to frequent transfusions. It had been started by her outpatient hematologist 10 days before her admission for the BU test dose. She discontinued the drug 2 weeks before her second admission for SCT. This correlation implicates deferasirox as potentially changing the BU concentrations and yielding higher than expected levels. Once the drug was stopped, PK studies demonstrated lower BU drug levels. This is the first reported case to show that the coadministration of deferasirox and BU may result in supratherapeutic BU concentrations. Deferasirox is an ironchelating agent indicated in the treatment of chronic iron overload due to blood transfusions. 8 Deferasirox primarily undergoes glucoronidation by UGT1A1, with minimal oxidative metabolism through the cytochrome P-450 (CYP) system. 9 This leads to competitive inhibition for the enzyme and increased BU concentrations. Co-administration with deferasirox yielded a BU AUC that was 1.5 times higher than the level that was determined when we discontinued the drug (1868 vs 1173 mM min). Iron overload seems to be a common problem in patients who undergo SCT and may increase the risk of complications such infections, venoocclusive disease and acute and/or chronic GVHD. 10 Although there is currently no evidence regarding the benefit of iron-chelating therapy on long-term morbidity and mortality in adult SCT recipients, screening to identify high-risk patients and initiation of iron-chelating drugs such as deferasirox is increasing among SCT centers. Because i.v. BU is largely used in conditioning regimens for SCT, the identification of drugs potentially affecting BU PK seems of importance.
There are currently no published cases or PK studies that report this drug interaction between BU and deferasirox. Identification of such potential drug-drug interactions should expand the use of therapeutic drug monitoring to quantify these effects and individualize the dose for each patient. Pre-transplant BU test dose allows the potential to target the dose of BU within any desired therapeutic window and to further quantify the magnitude of drug interactions with BU. 
